For all the human data they have around cancer and MND mpl is yet to be proven effective against either one, yes the data indicates that it maybe effective against both but only a phase 2 trial in both will give the absolute answer.
With the cost to run the phase 2 / 3 MND trial between $20m and $30m PAA dont have the money to conduct any trial atm.
MPL in canines failed to reach the stated end points but did show it improved life expectancy and quality of life.
The small trial planned in the USA requires at least 10 dogs to be enrolled, not sure of what end points are required for MPL to gain registration as a new cancer treatment for canines.
Remember during the phase 2B trial they could only get 3 dogs to register in the USA.
For all the human data they have around cancer and MND mpl is...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $71.26M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.0¢ | $119.0K | 679.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 235714 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 190570 | 5 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
18.0¢ |
Change
0.000 ( 2.86 %) |
||||
| Open | High | Low | Volume | ||
| 17.5¢ | 18.0¢ | 17.5¢ | 48353 | ||
| Last updated 15.51pm 24/05/2024 ? | |||||
| PAA (ASX) Chart |